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Chronic myeloid leukemia (CML) is a clonal
myeloproliferative  disorder  with  a  specific
genetic abnormality, the Philadelphia chromo-
some (Ph) translocation t(9;22)(q34;q11) gen-
erating the BCR-ABL1 gene fusion. The role of
the  Philadelpia  chromosome  translocation
t(9;22)(q34;q11) in CML development is well
documented and early in the chronic phase of
the disease it is the sole chromosome anomaly
in the majority of patients with CML. By con-
trast, disruption of the mixed lineage leukemia
(MLL) gene located on 11q23 is a recurrent
genomic change in acute leukemia and is par-
ticularly  prevalent  in  secondary,  acute
myeloblastic leukaemia (AML), arising follow-
ing cytotoxic treatment.While the dual combi-
nation  of  11q23  rearrangement  and  the  Ph
translocation has been described in a several
CML patients, the rearrangement of MLL gene
was confirmed only in rare cases.1-4 We report
a  case  of  combination  of  the  Philadelphia
translocation  t(9;22)(q34;q11)  and  t(11;19)
(q23;p13.1) in a CML patient who developed
accelerated phase of the disease while on ima-
tinib. The patient, a 28-years old female was
diagnosed with Ph-positive CML in December
2003. She was treated with hydroxyurea until
January  2006  when  she  was  pregnant  26
weeks. Treatment with interferon-ʱ (IFN) was
started and she delivered a normal baby, but
failed  to  achieve  complete  cytogenetic
response. From September 2006, she switched
to imatinib with an initial dose of 400 mg/day
resulting  in  a  complete  hematological  and
cytogenetic  remission  6  months  later.  She
maintained her complete response until March
2008, when 25% of the examined metaphases
showed  the  Philadelphia  translocation.  The
initial dose was increased to 600 mg/day, but 6
month later she developed accelerated phase
of  the  disease.  A  complete  blood  count
revealed:  hemoglobin,  8.9.  g/dL,  leukocyte
count  11.6ﾥ109/L  (neutrophils  38%,  lympho-
cytes  26%,  monocytes  23%,  myelocytes  3%,
metamyelocytes 6%; blasts 4%) and platelets
125ﾥ109/L.  Bone  marrow  aspirate  showed
hypercellularity  with  a  predominance  of
myeloid  cells  including  including  17%
myeloblasts  (promyelocytes  1.5%,  myelocytes
22%, metamyelocytes 27%, lymphocytes 7.5%,
poly  12%,  eryhroblasts  13%).  Chromosome
analysis performed from bone marrow aspira-
tion  revealed  100%  Ph-positive  metaphases
and  a  new  cytogenetic  finding,  a
t(11;19)(q23;p13) in 18 out of the 20 examined
metaphases. FISH analysis showed 95% BCR-
ABL1 positive cells. MLL rearrangement was
identified  using  the  LSI  MLL  (11q23)  Dual
Color  Break  Apart  Rearrangement  probe
(Vysis)  revealing  80%  of  cells  with  MLL
rearrangement.  The  disruption  of  MLL was
confirmed in metaphases demonstrating that
the distal part of the MLL was juxtaposed to the
der(19)  chromosome,  adjacent  to  the  cen-
tromeric  region  (Figure  1).  Treatment  with
Tasigna  (400  mg/day)  was  started,  but  2
months later her leukocyte count increased to
100ﾥ109/L  with  19%  blasts.  Serum  biochem-
istry was remarkable for lactatdehydrogenase
1014 U/L and GGT 70 U/L. One month later, she
developed  fever,  progressive  dyspnoea  and
tachycardia and she ultimately died one month
later. 
While CML progression is frequently accom-
panied by nonrandom secondary changes, the
mechanism(s) responsible for severe block in
differentiation  and  apoptosis  remains  poorly
understood.  The  acquisition  of  t(11;19)
(q23;p13.1) and its underlying MLL rearrange-
ment in our patient is an unusual finding and
raises  several  questions.  Firstly,  the
t(11;19)(q23;p13.1)  fusing  the  MLL gene  on
chromosome 11q23 with the ELL (MEN) gene
at 19p13.1 is found in a large proportion of
AML  patients  who  have  been  treated  by
chemotherapy,5,6 raising  the  possibility  that
the acquisition of MLL rearrangement in our
patient  is  the  direct  consequence  of  toxic
treatment. However; in our case hydroxyurea
and interferon was administrated, followed by
imatinib  therapy  for  about  2  years,  arguing
against a direct genotoxic effect of imatinib. In
addition,  the  aberration  is  not  limited  to
chemotherapy-related  mutagenesis  and  has
also  been  identified  in  association  with  de
novo myeloid leukemias. Therefore, it is more
likely that the cytogenetic evolution observed
in our case may represent the changing natu-
ral history of CML. 
The mechanisms is unclear, however con-
sidering MLL's central role as a major player in
leukemia,  it  is  likely  that  the  t(11;19)
(q23;p13.1) observed in our patient is a form of
cytogenetic evolution that play a direct role in
CML progression in the same way that results
in acute leukemia de novo. The critical contri-
bution of MLL-ELL fusion protein on the prolif-
erative potential of myeloid progenitors as well
as  its  causal  role  in  the  genesis  of  acute
myeloid  leukemias  was  demonstrated  using
transgenic animal models,7,8 though the pre-
cise  mechanism  remains  elusive.  Further
question may be raised regarding the direct or
indirect role of BCR-ABL1 in transition, sug-
gesting that the acquisition of MLL rearrange-
ment may be the consequence of genetic insta-
bility promoted by BCR-ABL1. Noteworthy, our
patient received treatment with hydroxyurea
only for about 2 years. While on imatinib ther-
apy, she maintained her complete cytogenetic
response  for  only  18  months.  She  remained
BCR-ABL1 positive by molecular methods dur-
ing the course of the disease. It is unclear, if
and how incomplete supression of BCR-ABL1
tyrosine kinase activity facilitated the develop-
ment of MLL disruption. As MLL fusion pro-
teins are dependent on hyperactive signalling
from stem cell receptor tyrosine kinases, it can
be hypothesed that kinase activity in our case
could be of crucial importance. In addition, it
has been shown, that the loss of ELL function
and overexpression of the MLL-ELL have anti-
apoptotic effects. Therefore, the acquisition of
t(11;19) could result in survival of cells that
otherwise  may  have  been  destined  to  die,
which could contribute to the development and
maintenance  of  imatinib  resistance  in  our
patient. A case similar to ours was reported by
Suzuki and all,9 describing a 33-years old CML
patient who was initially treated with interfer-
on-ʱ and  hydroxyurea  but  failed  to  achieve
complete cytogenetic response. One year later,
the patient developed blastic phase and a sec-
ondary  karyotypic  change  of  t(11;19)
(q23;p13.3).  Treatment  with  chemo  therapy
and  imatinib  was  administrated,  but  the
patient failed to achieve remission and died
five months later. Similar to our case, the clin-
ical course of this patient was aggressive and
unresponsive to imatinib treatment.
The dual combination of 11q23 aberration
and Ph is an infrequent phenomenon and has
only rarely been reported in CML. These cases
have been reported almost exclusively in asso-
ciation with disease acceleration or onset of
blast crisis, suggesting the direct role of MLL
in  transformation.  As  the  chromosomal
translocation  t(11;19)(q23;p13)  is  a  subtle
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genetic anomaly and may be easily overlooked
by standard cytogenetic analysis, our case fur-
ther  reinforce  the  importance  of  FISH  in
revealing  cryptic  balanced  translocations
involved in CML progression.10
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Figure 1. Karyotype of the patient showing simultaneous occurrence of t(9;22)(q34;q11)
and t(11;19)(q23;p13.1) (A). FISH using a MLL dual-color, break-apart probe revealing
the juxtaposition of the distal part of the MLL gene from chromosome 11 to the der(19)
chromosome, adjacent to the centromeric region (red signal) (B).